CAPA Blog

FDA Approves the First Non-Opioid Treatment for Management of Opioid Withdrawal Symptoms in Adults

FDA (05/16) – The U.S. Food and Drug Administration today approved Lucemyra (lofexidine hydrochloride) for the mitigation of withdrawal symptoms to facilitate abrupt discontinuation of opioids in adults. While Lucemyra may lessen the severity of withdrawal symptoms, it may not completely prevent them and is only approved for treatment for up to 14 days. Read more

Leave a Reply

Your email address will not be published. Required fields are marked *